rofecoxib has been researched along with Amyotrophic Lateral Sclerosis in 1 studies
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| " As prostaglandin E2 levels in spinal cord or in plasma were not reduced by Rofecoxib treatment, these results may suggest lack of sufficient bioavailability as the reason for the modest clinical changes observed." | 1.33 | Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS. ( Azari, MF; Cheema, SS; Hirst, J; Le Grande, MR; Lopes, EC; Petratos, S; Profyris, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azari, MF | 1 |
| Profyris, C | 1 |
| Le Grande, MR | 1 |
| Lopes, EC | 1 |
| Hirst, J | 1 |
| Petratos, S | 1 |
| Cheema, SS | 1 |
1 other study available for rofecoxib and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Blotting, Western; Cyclooxygenase Inhibitors; Dinoprostone; | 2005 |